Professor Leedman is Director of the Harry Perkins Institute of Medical Research, an endocrinologist, the Head of the Laboratory for Cancer Medicine, Chairman of Linear Clinical Research Ltd and co-founder of biopharmaceutical company MiReven. He completed his medical training at The University of Western Australia (UWA), specialising in endocrinology. He undertook his PhD at the Walter and Eliza Hall Institute in Melbourne and Post-doctoral Fellowship at Harvard Medical School in Boston. Professor Leedman returned to Perth in 1994 as a Senior Lecturer in Medicine at UWA, becoming a Professor of Medicine at UWA/Royal Perth Hospital in 2003, a role he holds today. His research team is developing new RNA-mediated ways to treat primary liver cancer and to overcome the all too frequent resistance to current therapies in advanced disease. He became a Fellow of the Australian Academy of Health and Medical Sciences in 2016.

Professor Tirnitz-Parker is a tenured Research Academic in the Curtin Medical School. She completed her undergraduate degree at the Johannes Gutenberg-Universität in Mainz Germany before undertaking a PhD at the University of Western Australia.

She was recruited to Curtin University as an independent Laboratory Head in 2011 and is now the Liver Cancer Program Lead at the Curtin Health Innovation Research Institute. 

As a translational researcher, Professor Tirnitz-Parker has served the Gastroenterological Society of Australia (GESA) in many roles over the years, including as Research & Grants Committee Chair, Australian Liver Association Executive Committee Member and currently as elected Board Director (2021-2023 term).

In 2019, Professor Tirnitz-Parker edited the book ‘Hepatocellular Carcinoma’ (Codon Publication) and was a member of the largest-ever all-female expedition to Antarctica with the International leadership program for women scientists ‘Homeward Bound’.

Dr Wallace is a consultant hepatologist and gastroenterologist who graduated from the University of Western Australia and underwent specialist training in gastroenterology and hepatology at Sir Charles Gairdner Hospital and Royal Perth Hospital.

After completing his specialist training, he undertook a Post-doctoral Fellowship at the Mount Sinai School of Medicine in New York City, where his research areas included hepatocellular carcinoma and the treatment of liver fibrosis, he completed his PhD at UWA in the area of HCC.

Dr Winteringham is a cancer biologist and leads the Translational Cancer Research Program at the Perkins. She has over twenty-five years’ experience in discovery cancer research, focused on understanding the biochemistry and molecular genetics of novel cancer genes. Dr Winteringham is the CI for the Perkins Cancer Biobank which  includes both biospecimens and laboratory generated research data. Integrating these data with extensive clinical data will support a precision medicine approach to cancer treatment.